Ted Schenkelberg | Managing Partner
Next Frontier Advisors

Mr. Ted Schenkelberg (MBA/MPH), for over 25 years experience working in the vaccine and global health field. Currently, Ted is a Managing Partner at Next Frontier Advisors (NFA), a strategic consulting firm advising foundations, companies, universities and philanthropies in the vaccines, biomedical and global health fields. At NFA, Ted has led efforts to catalyze work in the Alzheimer’s vaccine space. Previously, Ted served as Co-Founder, Chief Operating Officer and Chief Strategy Officer at the Human Immunome Project (formerly the Human Vaccines Project), a global NGO working to catalyze AI-based models of the immune system with collaborations. Prior, Ted led business planning at the International AIDS Vaccine Initiative (IAVI), an NGO operating in 21 countries which has raised over $1 billion for vaccine R&D. He also served as an Equity Analyst and member of the Investment Committee at Carnegie Capital, an asset management firm which oversaw $1 billion in management and administration. Ted currently serves as a board member at Doctors of the World USA, Vital Strategies and MesaNova Bio and previously served as a board member at the African Services Committee, and the Human Immunome Project European Foundation. Ted was trained at the Johns Hopkins (MPH) and University of Chicago (MBA). He has also held a post as a Visiting Scientist at the Harvard Chan School.

Appearances:

Pre-Congress Workshops - Monday 30th March @ 10:00

CHRONIC DISEASE, AUTOIMMUNITY & THE VIROME WORKSHOP (AM)

CHRONIC DISEASE, AUTOIMMUNITY & THE VIROMERoom 204C

Exploring the drivers and development of vaccines against non-infectious disease targets.

10am Chair’s opening remarks: Please introduce yourself and give a brief overview of the sessions to be covered throughout the day before introducing the speakers on stage for the opening panel.Dr Michael Caldwell, Assoc VP Vaccine Research & Education, Meharry Medical College

10:05am Panel: Adjuvants and Immunity: Exploring Systemic Benefits Beyond Zoster- Beyond Shingles: Explore emerging data linking zoster vaccines to reduced risks of cardiovascular disease and Alzheimer’s.- Immunological Insights: Discuss how zoster vaccines adjuvant systems may drive systemic immune benefits beyond zoster prevention- Correlates of Protection: Identify immune markers that may explain long-term protection and -potential cross-disease benefits.- Public Health Implications: Debate whether zoster vaccines should be recommended earlier in life for chronic disease prevention.- Future Research: Outline next steps for validating these findings and applying the model to other latent viruses like EBV.Moderator: Jay Evans, Chief Scientific and Strategy Officer, InimmuneDr Bali Pulendran, Professor, Director, Institute for Immunity, Transplantation and Infection, Stanford University School of MedicineDr Ofer Levy, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children’s Hospital, Professor, Harvard Medical School Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford UniversityDr Ken J. Ishii, Director and Professor, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo

11:00 Uncovering the Immune Landscape of Autoimmune Disease: From Parkinsons to ALSDr Emil Johansson, Senior Scientist, Neurodegeneration Program Lead, La Jolla Institute for Immunology

11:30 The shingles vaccine and dementia: A causal relationship?Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University

12:00 Clinical Development of a TLR4 Agonist in Phase 2 Trials for Allergic RhinitisDr Shannon Miller, VP of Operations, Inimmune

12:30 Accelerating Development of Vaccines for Prevention and Control of Alzheimer’s Disease: The Alzheimer’s Vaccine InitiativeTed Schenkelberg, Managing Partner, Next Frontier Advisors

Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University